HK1129590A1 - Multiple unit type sustained release oral formulation and process for the preparation thereof - Google Patents

Multiple unit type sustained release oral formulation and process for the preparation thereof

Info

Publication number
HK1129590A1
HK1129590A1 HK09107836.4A HK09107836A HK1129590A1 HK 1129590 A1 HK1129590 A1 HK 1129590A1 HK 09107836 A HK09107836 A HK 09107836A HK 1129590 A1 HK1129590 A1 HK 1129590A1
Authority
HK
Hong Kong
Prior art keywords
preparation
sustained release
unit type
multiple unit
oral formulation
Prior art date
Application number
HK09107836.4A
Other languages
English (en)
Inventor
Hyun Jung Noh
Cheong Weon Cho
Jeong Ku
Taek Rho Kim
Hee Chol Kang
Qing Ri Cao
Eun Young Yang
Tae Kun An
Eun Kyung Jeon
Jae Kyoung Ko
Hye Suk Hong
Il Hwan Kim
Hea Ran Suh
Hye Jin Han
Gang Soo Chae
Original Assignee
Cj Cheiljedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Cheiljedang Corp filed Critical Cj Cheiljedang Corp
Publication of HK1129590A1 publication Critical patent/HK1129590A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK09107836.4A 2006-01-27 2009-08-25 Multiple unit type sustained release oral formulation and process for the preparation thereof HK1129590A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060009057A KR100762847B1 (ko) 2006-01-27 2006-01-27 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
PCT/KR2007/000439 WO2007086692A1 (en) 2006-01-27 2007-01-25 Multiple unit type sustained release oral formulation and process for the preparation thereof

Publications (1)

Publication Number Publication Date
HK1129590A1 true HK1129590A1 (en) 2009-12-04

Family

ID=38309433

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09107836.4A HK1129590A1 (en) 2006-01-27 2009-08-25 Multiple unit type sustained release oral formulation and process for the preparation thereof

Country Status (7)

Country Link
US (1) US20080305165A1 (de)
EP (1) EP1976489B1 (de)
JP (1) JP4969586B2 (de)
KR (1) KR100762847B1 (de)
CN (1) CN101374505B (de)
HK (1) HK1129590A1 (de)
WO (1) WO2007086692A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5714910B2 (ja) * 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
JP2011512406A (ja) * 2008-02-22 2011-04-21 ハナル バイオファーマ カンパニー リミテッド 複合製剤
CN102014881A (zh) * 2008-02-22 2011-04-13 韩兀生物制药株式会社 药物制剂
US20110052683A1 (en) * 2008-02-22 2011-03-03 Hanall Biopharma Co., Ltd. Pharmaceutical preparation for treating cardiovascular disease
KR101181172B1 (ko) * 2008-02-22 2012-09-18 한올바이오파마주식회사 방출성이 제어된 시간차 투여 약제학적 제제
UY31698A (es) 2008-03-11 2009-11-10 Takeda Pharmaceutical Preparacion solida de desintegracion oral
WO2009125944A2 (ko) * 2008-04-10 2009-10-15 한올제약주식회사 비디히드로피리딘계 칼슘 채널 차단제 및 안지오텐신-2 수용체 차단제를 포함하는 약제학적 제제
EP2275093A2 (de) * 2008-04-10 2011-01-19 HanAll Biopharma Co., Ltd. Pharmazeutische formulierung
WO2009125987A2 (ko) * 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
KR101205633B1 (ko) * 2008-04-29 2012-11-27 한올바이오파마주식회사 심혈관계 질환 치료용 약제학적 제제
WO2009134057A2 (ko) * 2008-04-29 2009-11-05 한올제약주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
WO2009134053A2 (ko) * 2008-04-29 2009-11-05 한올제약주식회사 방출성이 제어된 차이자이드계 화합물과 안지오텐신 - ii - 수용체 차단제를 포함하는 약학적 조성물
WO2009151295A2 (ko) * 2008-06-13 2009-12-17 한올제약주식회사 아젤니디핀과 ＨＭＧ－ＣｏＡ 환원효소 억제제 또는 안지오텐신 Ⅱ 수용체 차단제를 포함하는 약제학적 제제
WO2010008203A2 (ko) * 2008-07-15 2010-01-21 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
WO2010008244A2 (ko) * 2008-07-18 2010-01-21 한올제약주식회사 약제학적 제제
KR20100045344A (ko) * 2008-10-23 2010-05-03 한올바이오파마주식회사 방출성이 제어된 베타 아드레날린 차단제와 ＨＭＧ-ＣｏＡ 환원 효소 억제제의 신규 복합 조성물
WO2010098627A2 (ko) * 2009-02-27 2010-09-02 한올바이오파마주식회사 약제학적 제제
KR20110129405A (ko) * 2009-02-27 2011-12-01 한올바이오파마주식회사 약제학적 제제
WO2011028016A2 (ko) * 2009-09-04 2011-03-10 한올바이오파마주식회사 베타 아드레날린 차단제와 안지오텐신-2 수용체 길항제를 포함하는 약제학적제제
CN102548544B (zh) * 2009-10-09 2015-01-21 永进药品工业株式会社 同时具有速效特性和长效特性的药物组合物
KR101137467B1 (ko) * 2009-11-02 2012-04-20 안국약품 주식회사 테오브로민 함유 서방성 정제
MY161846A (en) 2010-07-09 2017-05-15 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
KR101220830B1 (ko) * 2010-08-18 2013-01-10 안국약품 주식회사 테오브로민의 서방성 과립제 및 그 제조방법
KR101675501B1 (ko) * 2011-11-02 2016-11-14 한국유나이티드제약 주식회사 클로피도그렐 및 아스피린의 복합제제
CA2860098A1 (en) * 2011-12-22 2013-06-27 Boehringer Ingelheim International Gmbh Immediate release multi unit pellet system
WO2014119767A1 (ja) * 2013-01-31 2014-08-07 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
JP6086857B2 (ja) * 2013-11-15 2017-03-01 ティーエスフーズ株式会社 冷凍餃子及び冷凍餃子の製造方法
CN105267173A (zh) * 2014-05-30 2016-01-27 北京星昊医药股份有限公司 一种吡贝地尔缓释片及其制备方法
WO2016015814A1 (de) 2014-07-30 2016-02-04 Merck Patent Gmbh Pulverförmige, direkt verpressbare polyvinlalkohol-typen
BR112017001758A2 (pt) * 2014-07-30 2017-11-21 Merck Patent Gmbh álcoois polivinílicos diretamente compressíveis
CA2956538C (en) 2014-07-30 2023-01-03 Merck Patent Gmbh Directly compressible composition comprising microcrystalline cellulose
KR101642193B1 (ko) * 2014-10-13 2016-07-25 씨제이헬스케어 주식회사 메트포르민 서방성 제제 및 그의 제조방법
KR101869406B1 (ko) * 2015-11-25 2018-07-24 한국유나이티드제약 주식회사 방출제어형 경질캡슐 제제
CN106236731A (zh) * 2016-08-30 2016-12-21 佛山市弘泰药物研发有限公司 一种扎托布洛芬胶囊及其制备方法
US20190307698A1 (en) * 2016-12-14 2019-10-10 Merck Patent Gmbh Directly compressible matrix for the production of tablets having extended release of active pharmaceutical ingredient
TW201834643A (zh) * 2017-02-20 2018-10-01 韓商西梯茜生命工學股份有限公司 Kr 南韓 包含鹽酸依托必利之速釋和緩釋藥物製劑
KR20200077911A (ko) * 2018-12-21 2020-07-01 (주)유케이케미팜 잘토프로펜 함유 서방성 의약 조성물
KR20210085215A (ko) * 2019-12-30 2021-07-08 주식회사 대웅제약 안정성이 향상된 약제학적 제제 및 그 제조 방법
CN111759818B (zh) * 2020-08-04 2021-10-01 重庆康刻尔制药股份有限公司 一种盐酸二甲双胍缓释片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2093200A (en) * 1936-07-31 1937-09-14 Libke Russell Electrical switch
US4002731A (en) * 1974-06-17 1977-01-11 Sterling Drug Inc. Diagnostic process using sodium tyropanoate
JPS604120A (ja) * 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
KR970003126B1 (ko) * 1988-02-27 1997-03-14 니혼 노야꾸 가부시끼가이샤 디티올란 유도체
JP3677156B2 (ja) * 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
ID29852A (id) * 1998-11-02 2001-10-18 Elan Corp Plc Cs Komposisi pelepasan modifikasi multi partikulasi
US6685928B2 (en) * 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
CZ300745B6 (cs) * 1999-12-22 2009-07-29 Pharmacia Corporation Kompozice inhibitoru cyklooxygenázy-2 s dvojím uvolnováním
JP4280074B2 (ja) * 2001-04-25 2009-06-17 大正製薬株式会社 マルチプルユニット型徐放性錠剤
SI21301A (sl) * 2002-09-11 2004-04-30 LEK farmacevtska družba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법

Also Published As

Publication number Publication date
US20080305165A1 (en) 2008-12-11
JP4969586B2 (ja) 2012-07-04
EP1976489B1 (de) 2012-07-18
EP1976489A1 (de) 2008-10-08
JP2009524651A (ja) 2009-07-02
CN101374505B (zh) 2013-07-17
KR100762847B1 (ko) 2007-10-04
KR20070078625A (ko) 2007-08-01
EP1976489A4 (de) 2011-04-13
WO2007086692A1 (en) 2007-08-02
CN101374505A (zh) 2009-02-25

Similar Documents

Publication Publication Date Title
HK1129590A1 (en) Multiple unit type sustained release oral formulation and process for the preparation thereof
HUS1800043I1 (hu) 514 számú gyógyszerkészítmény
HK1138203A1 (en) Method for preparing rapidly disintegrating formulation for oral administration and the products thereof
ZA200904436B (en) Modified release ibuprofen solid oral dosage form
PL2484223T3 (pl) Systemy podawania doustnego z kontrolowanym uwalnianiem
IL199006A0 (en) Nanoparticulate formulations and methods for the making and use thereof
ZA200705530B (en) Sustained release pharmaceutical formulations
EP2123260A4 (de) Liposom-formulierung und verfahren zu ihrer herstellung
ZA200802602B (en) Controlled release formulation
EP2043647A4 (de) Formulierung mit gesteuerter freisetzung und entsprechende verfahren
EP2011482A4 (de) Feste zubereitung zur oralen applikation
HK1121970A1 (en) Sustained release pharmaceutical formulation comprising phenylephrine
EP2178893A4 (de) Orale formulierungen für picoplatin
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
ZA200808489B (en) Nicotine-carrier vaccine formulation
IL189648A (en) The Buzadoxipan acetate composition and process for their preparation
GB0614586D0 (en) Pharmaceutical Formulation
HK1129566A1 (en) Oral preparation comprising pioglitazone
EP2138168A4 (de) Mittel zur oralen verabreichung und herstellungsverfahren dafür
EP1976490A4 (de) Zaltoprofenhaltige tablette mit verzögerter freisetzung und herstellungsverfahren dafür
EP1753405A4 (de) Pharmazeutische formulierung mit kontrollierter freisetzung
EP1941896A4 (de) Dipeptid-haltige zusammensetzung zur oralen verabreichung
EP2167468A4 (de) Verfahren zur herstellung und pharmazeutische formulierungen von 4-chinolinonen und chinolinen und deren verwendung
IL198760A0 (en) Oral formulations
ZA200904654B (en) Tablet formulation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220125